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Introduction:
In Washington State, marijuana legalization occurred for medicinal purposes in 1996 and for recreational use in 2012. [1] Cannabis based therapies have been suggested for a broad range or problems including anxiety, insomnia, chronic pain, depression and epilepsy. [2] Publication of prospective trials supporting adjunctive use of cannabidiol oil (CBD) for the reduction of convulsive seizure burdens in patients with Dravet (DS) and
Lennox-Gastaut syndromes (LGS) occurred in 2017. [3, 4] In our Epilepsy clinic, patient inquiries regarding efficacy of cannabis have increased since 2012 and yet more since those landmark trials and with the USA Food and Drug Administration's rescheduling of CBD in 2018. Specifically many patients are prepared to discuss cannabis in epilepsy clinic well versed in their extensive reviews of various online and anecdotal resources, but with limited understanding of available peer-reviewed literature, including side effects apparent in the 2017 LGS and DS trials or from studies of artisanal cannabis use in epilepsy. [1, 3, 4] Extensive patient preparation for cannabis use could be viewed as a version of selfdetermined theory (SDT), an approach that helps build an effective provider/patient dyad, particularly if a provider supports the patient's therapy choice. [5] An autonomous example of SDT might be a patient's decision to pursue a vegetarian diet in the setting of elevated blood fats. An example of an autonomous support model of SDT would be a provider endorsing patient therapy choices from among provider-suggested conventional anti-seizure medications that the patient reviewed-on their own-prior to
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clinic visit, perhaps on Epilepsy Foundation websites. Their choice is supported and refined with provider input based on more extensive literature review, standards of care, urgency of treatment, benefit vs. cost discussions and other patient-specific clinical data. That supportive patient/physician dyad can lead to motivation for continued wellbeing and therapy adherence. SDT works when the relative benevolence of the treatment is known by both parties. We are concerned patients and providers are not well prepared to discuss self-determined therapy with cannabis (SDTC) risks. Among our patients, SDTC are perceived as having minimal morbidity. Perhaps the most common perception is SDTC are natural and therefore safe. We have yet to hear patient concerns of mortality risks. Perhaps just as importantly, the literature does not reflect caregiver concerns of SDTC mortality risks, this may be in part because artisanal cannabis therapies may be vaped, smoked, applied as creams or tinctures, ingested as oils, drops or tablets, and combined with varied CBD to tetrahydrocannabinol ratios. It is hard to keep track of the what, how, where and when of SDTC, let alone risks of them.
[1]
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Case reports
With institutional approval, we used medical records to report two deaths of patient's whose reliance on SDTC for seizure prevention may not have been benevolent. We classify their deaths based on Nashef SUDEP criteria. [6] Cases appear on Table 1 for ease of review. In brief patient one had generalized epilepsy and had moved away from zonisamide therapies to SDTC. Shortly after completing a clinic visit, he returned to his vehicle, never started it, and was found deceased in the vehicle with no suspicious circumstances evident. Post mortem data of gene test (epiSEEK® triome, Cortagen, 2016) results for is available (Appendix A). Patient two also relied on SDTC and had self-weaned from conventional therapies for treatment of her focal epilepsy. She likely seized while showering, obstructed the drain, and had irreversible injuries from drowning despite in-field resuscitation. Both patients were in their twenties.
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Discussion
Sudden unexpected death in epilepsy (SUDEP) risks are highest with poor control of primary or secondary generalized tonic-clonic seizures. [7] In this case series we do not calculate risk given we do not know the denominator of patients using primarily SDTC to treat their epilepsy. Substance abuse compounds SUDEP risk, though literature searches combining SUDEP and search terms of cannabis or marijuana show few results. Legalization of cannabis has shifted public opinion and diminished risk perceptions. [8] We think SDTC may potentially jeopardize epilepsy control, particularly when cannabis is substituted for conventional anti-seizure medications or when the pharmacology of varied forms of artisanal cannabis remains undetermined. In these two reported cases, reliance on SDTC may have worsened outcomes leading to one probable SUDEP and one drowning associated death. Marijuana use has known risks of dependency and withdrawal, while long-term use is associated with declines in memory and higher rates of mood-disorders. [8] Cannabidiol oil may be useful in treating convulsive events in Lennox Gastaut and Dravet syndromes, however, we speculate that confidence in SDTC therapies may be risky and should be tempered by neurology provider guidance, particularly with new data and studies relating SDTC therapies to morbidities and/or sudden mortality in patients with epilepsy. [2, 3, 7] 
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Conclusion
Two cases of sudden death are reported in patients whose self-determined seizure control primarily relied on artisanal cannabis therapies. Risks of morbidity, mortality and SUDEP in SDTC users needs to be further studied. Providers should be aware of the absence of morbidity and mortality data for SDTC in patients with epilepsy may only be due to a failure of reporting. Highlights:
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• Self-determined tendencies to use cannabis (SDTC) monotherapy may occur in some patients
• Two cases of SDTC monotherapy had associated mortality
• The decision to use cannabis monotherapy may not be a benign substitute for traditional anti-seizure drugs
